THE HAGUE, Netherlands & CHICAGO – Haga Teaching Hospital, digital health platform provider physIQ and biosensor technology provider VitalConnect are collaborating on a study that will evaluate how wearable biosensors and artificial intelligence-based analytics can augment clinical care for patients in treatment for cancer. The study is being funded by Janssen Pharmaceuticals.
In the study, patients being treated with either erythrocyte transfusion or chemotherapy, either with or without immunotherapy, will be provided VitalPatch biosensors that collect and stream physiological data via physIQ’s pinpointIQ platform. The goal of the study is to evaluate how continuous physiological data coupled with sophisticated personalized analytics can provide early clinical indication of adverse events sometimes associated with anti-cancer treatment.
“Immunotherapy and other anti-cancer treatments offer great hope for patients managing hematological diseases,” said Dr. Martin Schipperus, chair of hematology at Haga Teaching Hospital, in a statement. “However, these same powerful agents can also result in side effects that may impact patients’ ability to tolerate treatment. By monitoring patients this way, we hope to identify a novel approach to proactively identifying and managing adverse events that may otherwise negatively impact patient outcomes.”
Through the physIQ pinpointIQ solution, clinical-grade vital signs stream continuously from the VitalPatch biosensor to the cloud. Patients in the study will begin wearing the biosensor several days prior to the treatment to allow the physIQ artificial intelligence-based analytics to develop a pre-treatment personalized baseline. Patients will then continue to wear the VitalPatch, both during and after treatment in the clinic. By comparing each patient to their own personalized baseline, clinicians will be able to continuously monitor their physiological response throughout treatment and afterwards, even when the patients have returned home.
“AI-based analytics and wearable biosensors hold great promise for monitoring at-risk patient populations at home, at work, in the clinic, and all places in between” said Dr. Stephen Ondra, chief medical officer of physIQ. “We are excited by the prospect of evolving the standard of care to use personalized proactive information to improve outcomes.”
The pinpointIQ solution, its personalized analytics and the VitalPatch biosensor are being deployed in various clinical environments to support clinicians caring for at-risk patient populations. The end-to-end solution is also being provided to pharmaceutical and medical device companies that are integrating real-world data sets into clinical trials.
“Every year we see better treatments available in oncology which is very encouraging,” said Schipperus, “But beyond drugs alone there is need to improve the patient experience and we are excited about the innovations now available to potentially improve how these patients are cared for.”